The compounding decision most practices get wrong.
When a compounding partnership stalls, the pharmacy is rarely the problem. Usually the orders were routed to the wrong kind of pharmacy from the start.
In this article
The first month with a new compounding pharmacy usually goes one of two ways. Either the orders flow and nobody thinks about the pharmacy again, or the office manager starts fielding calls: this order needs a patient name, that one can't ship as office stock, a third needs a new prescription.
When it goes the second way, the pharmacy is rarely the problem. The practice sent its orders to the wrong kind of pharmacy, and fixing that starts with a line federal law draws straight down the middle of compounding.
Two channels, two rulebooks
On one side is the traditional compounding pharmacy, known by the section of federal law that governs it, 503A. It prepares medication for an individual patient against a prescription, and its day-to-day oversight comes from the state board of pharmacy.
On the other side is the outsourcing facility, a category Congress created with the Drug Quality and Security Act of 2013. Outsourcing facilities register with the FDA, follow current good manufacturing practice, are inspected on a risk-based schedule, and report the products they make to the agency twice a year, as KPMG's review of the sector lays out. The FDA's own definition carries the detail that matters most to a practice: an outsourcing facility may or may not obtain prescriptions for identified individual patients.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Who oversees it | State board of pharmacy | FDA registration and inspection |
| Prescriptions | Required for an identified patient | May compound with or without one |
| Quality standard | USP compounding chapters | Current good manufacturing practice |
| Reports to the FDA | Not routinely | Products reported twice a year |
| Typical use | Dispensed to the patient | Office stock and products ready to administer |
FDA outsourcing facility registration guidance; KPMG, 2022
Route by how the drug is used
The simplest rule we know is to follow the medication to the patient. If it leaves your office in the patient's hands, or ships to their home, it's a 503A prescription. If your staff administers it in the office from stock on the shelf, it generally belongs with a 503B outsourcing facility. States can add their own conditions on office use, so it's worth confirming how yours handles it.
- Prescription for a named patient
- 503A pharmacy
- Dispensed to the patient
- Stock for in-office use
- 503B outsourcing facility
- Administered in your office
A customized hormone cream is a 503A order. So is an oral suspension made for a child who can't swallow tablets. Prefilled syringes used during procedures are 503B territory, and so are premixed bags and anything else that arrives ready to administer. Hospitals lean on outsourcing facilities for exactly this work: in KPMG's interviews with health systems, some reported sourcing 10 to 20 percent of their sterile injectable volume from 503Bs.
Most practices need both
Few practices live entirely on one side of the line. A dermatology group writes patient-specific prescriptions all day and also keeps sterile products on hand for procedures. A wellness clinic may dispense some therapies and administer others. Choosing one partner for everything forces workarounds, and the workarounds are where the friction comes from: prescriptions written for items that should be stock, orders sent back with questions, patients waiting on refills.
If nobody on staff can say which items are patient-specific and which are office stock, that's usually the first sign the routing needs work.
Setting it up
Start with an honest inventory: every compounded medication the practice prescribes or administers, how it's used, and roughly how much you go through in a month. Sort each item into patient-specific or office use. That list becomes your routing map.
Then match each side to a partner licensed for it. A 503A pharmacy should hold a license in every state where your patients live. A 503B facility should appear on the FDA's list of registered outsourcing facilities, which also shows when it was last inspected.
The last step is the one practices underestimate. Moving prescriptions away from an incumbent pharmacy touches e-prescribing settings, staff habits, and patient refills all at once. Pick a cutover date, give staff a one-page guide, and tell affected patients before the change rather than after it.
Talk to Northstra Health.
Northstra Health matches practices to contracted 503A and 503B partners based on what they prescribe and administer, manages the move away from incumbent pharmacies, and stays on the account after launch.
